What drove Novavax's strong Q1 performance?

The strong performance was driven by partner revenues, including milestone payments and supply sales from Sanofi and Pfizer.

Did Novavax provide future guidance?

No specific numerical guidance was given, but the company emphasized a focus on long-term partnerships.

Novavax Q1 Earnings Beat Wall Street Estimates

Q: Did Novavax beat earnings expectations in Q1?

Yes, Novavax exceeded Wall Street's revenue and earnings estimates for Q1 2026.

Q: How has Novavax's strategy changed?

The company shifted from direct commercial activity to a licensing and collaboration model with key partners.

Novavax delivered Q1 earnings above Wall Street estimates, fueled by milestone and supply payments from Sanofi and Pfizer. CEO John Jacobs highlighted the company's pivot to a licensing and collaboration model.

Novavax (NVAX) reported first-quarter results that exceeded Wall Street's revenue and earnings estimates, triggering a significant positive market reaction. Management attributed the strong quarter to partner-driven revenue streams, particularly milestone payments and supply sales tied to agreements with Sanofi and Pfizer.

Key Financial Results

Metric	Q1 2026	Estimates	Change
Revenue	Not disclosed	Not disclosed	—
Net Income	Not disclosed	Not disclosed	—
EPS	Not disclosed	Not disclosed	—

Note: The original source did not include specific figures.

Key Highlights from the Call

CEO John Jacobs emphasized the company's shift from direct commercial activity to a licensing and collaboration strategy, stating, "We now have either licensing or partnership arrangements with major players." He noted that Q1 revenue benefited significantly from milestone payments and supply sales from partners like Sanofi and Pfizer.

Guidance

No specific numerical guidance was provided during the call, but management indicated a continued focus on long-term partnerships and expanding existing collaborations.

Impact on the Stock

Novavax shares rose sharply following the earnings release, reflecting investor optimism about the company's ability to grow through its licensing model rather than direct sales.

What This Means for Investors

The Q1 results suggest that the strategic pivot to partnerships may be paying off, but investors should monitor the sustainability of these revenues and the company's ability to secure new deals.